Idebenone Mitigates Traumatic-Brain-Injury-Triggered Gene Expression Changes to Ephrin-A and Dopamine Signaling Pathways While Increasing Microglial Genes
Authors:
- Hyehyun HwangHHHyehyun Hwang
- Chinmoy SarkarCSChinmoy Sarkar
- Boris PiskounBPBoris Piskoun
- Naibo ZhangNZNaibo Zhang
- Apurva BorcarABApurva Borcar
- Courtney L. RobertsonCRCourtney L. Robertson
- Marta M. LipinskiMLMarta M. Lipinski
- Nagendra YadavaNYNagendra Yadava
- Molly J. GoodfellowMGMolly J. Goodfellow
- Brian M. PolsterBrian M. Polster
Open Access
Abstract
Traumatic brain injury (TBI) leads to persistent pro-inflammatory microglial activation implicated in neurodegeneration. Idebenone, a coenzyme Q10 analogue that interacts with both mitochondria and the tyrosine kinase adaptor SHC1, inhibits aspects of microglial activation in vitro. We used the NanoString Neuropathology Panel to test the hypothesis that idebenone post-treatment mitigates TBI-pathology-associated acute gene expression changes by moderating the pro-inflammatory microglial response to injury. Controlled cortical impact to adult male mice increased the microglial activation signature in the peri-lesional cortex at 24 h post-TBI. Unexpectedly, several microglial signature genes upregulated by TBI were further increased by post-injury idebenone administration. However, idebenone significantly attenuated TBI-mediated perturbations to gene expression associated with behavior, particularly in the gene ontology–biological process (GO:BP) pathways “ephrin receptor signaling” and “dopamine metabolic process”. Gene co-expression analysis correlated levels of microglial complement component 1q (C1q) and the neurotrophin receptor gene Ntrk1 to large (>3-fold) TBI-induced decreases in dopamine receptor genes Drd1 and Drd2 that were mitigated by idebenone treatment. Bioinformatics analysis identified SUZ12 as a candidate transcriptional regulator of idebenone-modified gene expression changes. Overall, the results suggest that idebenone may enhance TBI-induced microglial number within the first 24 h of TBI and identify ephrin-A and dopamine signaling as novel idebenone targets.Keywords
Funding Information
- National Institutes of Health (R01 NS112212, R01 NS115876)
This publication has 69 references indexed in Scilit:
- The role of CXCL12/CXCR4/CXCR7 axis in cognitive impairment associated with neurodegenerative diseasesBrain, Behavior, & Immunity - Health, 2024
- Idebenone alleviates doxorubicin-induced cardiotoxicity by stabilizing FSP1 to inhibit ferroptosisActa Pharmaceutica Sinica B, 2024
- Gene Set Knowledge Discovery with EnrichrCurrent Protocols, 2021
- NOX2 drives M1-like microglial/macrophage activation and neurodegeneration following experimental traumatic brain injuryBrain, Behavior, and Immunity, 2016
- Serum CXCL12 concentration in patients with severe traumatic brain injury are associated with mortalityClinica Chimica Acta, 2016
- Idebenone and neuroprotection: antioxidant, pro-oxidant, or electron carrier?Journal of Bioenergetics and Biomembranes, 2014
- The effects of idebenone on mitochondrial bioenergeticsBiochimica et Biophysica Acta (BBA) - Bioenergetics, 2012
- Metabotropic glutamate antagonist, MCPG, treatment of traumatic brain injury in ratsBrain Research, 1995
- Bcr‐Abl oncoproteins bind directly to activators of the Ras signalling pathway.The EMBO Journal, 1994
- Inhibition of lipid peroxidation by a novel compound (CV-2619) in brain mitochondria and mode of action of the inhibitionBiochemical and Biophysical Research Communications, 1984